Cambridge Investment Research Advisors, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.6 Billion
- Q1 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 117,120 shares of RXRX stock, worth $671,097. This represents 0.0% of its overall portfolio holdings.
Number of Shares
117,120
Previous 87,984
33.12%
Holding current value
$671,097
Previous $595,000
4.2%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding RXRX
# of Institutions
348Shares Held
284MCall Options Held
2.83MPut Options Held
3.64M-
Vanguard Group Inc Valley Forge, PA34MShares$195 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$185 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$142 Million0.13% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$99.2 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$84 Million0.44% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.03B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...